Schafer Boeder Selected Research

volagidemab

1/2018

Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Schafer Boeder Research Topics

Disease

4	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2021 - 01/2018
2	Hypoglycemia (Reactive Hypoglycemia) 01/2021 - 01/2021
2	Infections 01/2021 - 01/2019
2	Hypertension (High Blood Pressure) 01/2021 - 08/2015
2	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 01/2021 - 01/2019
1	COVID-19 01/2021
1	Type 2 Diabetes Mellitus (MODY) 01/2021
1	Body Weight (Weight, Body) 01/2019
1	Sleepiness 08/2015

Drug/Important Bio-Agent (IBA)

3	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2019
2	Insulin (Novolin)FDA Link 01/2019 - 01/2018
1	Immune Checkpoint InhibitorsIBA 01/2021
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2021
1	Sodium-Glucose Transport ProteinsIBA 01/2021
1	SodiumIBA 01/2019
1	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2019
1	SymportersIBA 01/2019
1	volagidemabIBA 01/2018
1	Glucagon Receptors (Glucagon Receptor)IBA 01/2018

Therapy/Procedure

1	Off-Label Use 01/2021
1	Continuous Positive Airway Pressure 08/2015